SYNTIRON, LLC.

Biotech · Private

Multivalent subunit vaccine against Staphylococcus aureus based on staphylococcal iron receptor proteins (SIRPs)

Grants
$530K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Multivalent Lipoprotein Vaccine to Prevent S. aureus Cutaneous Infections$298,656
Federal grantDepartment of Health and Human Services · Phase I · A Novel Vaccine to Prevent Urinary Tract Infections$231,517
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2985TIGATX INC——
2986Whisper Biosciences——
2987Singular Genomics——
2988SYNTIRON, LLC.——
2989ROCKETML, INC.——
2990ATHGHIN BIOTECHNOLOGY, INC.——
2991Twentyeight-Seven Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Compositions And Methods For Generating Immunity To Bacterial Infectionapplication
  • Compositions And Methods For Generating Immunity To Bacterial Infectionapplication
  • Compositions and Methods for Generating Immunity to Bacterial Infectionapplication
  • Compositions and Methods for Generating Immunity to Bacterial Infectionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.